Healthcare, Pharma & Life Sciences

120/80 Health Group Posts Eighth Straight Year of Record Growth

Image
120/80 Health Group Posts Eighth Straight Year of Record Growth

New York – September 29, 2026 -- 120/80 Health Group has logged its eighth consecutive year of record growth, fueled by new client wins and deepening relationships across healthcare and life sciences.

Top-10 biopharma and diagnostic firms sign on for AI-driven work

The firm added multiple category-leading clients in 2026 and began working with several top-10 global biopharmaceutical and diagnostic companies applying AI to drug, test and device development. The agency has shifted from brand-awareness communications for early-stage digital health startups to a strategic consultancy serving businesses from pre-Series A through publicly traded companies.

Massage Envy Opens $100,000 Grant Round, Lifts AMTA Funding to $550,000

Scottsdale, Ariz. – September 29, 2026 -- The American Massage Therapy Association (AMTA) will open applications October 1 for its ninth round of massage school grants funded by Massage Envy, offering ten $10,000 awards totaling $100,000. The fall cycle brings Massage Envy's cumulative funding of the program to $550,000.

Massage Envy doubles annual grant capacity in 2026

The program now distributes 10 grants per cycle in both spring and fall, up from five per cycle in prior years, effectively doubling annual grant availability for accredited massage schools.

Accredited schools can apply through October 31

Eligible massage schools must submit an online application via AMTA detailing how grant funds would support school programs and students. The application window runs October 1–31, 2026.

Acurx Enrolls First Patient in PATHFINDER Trial for Recurrent C. diff

Staten Island, N.Y. – September 29, 2026 -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has enrolled the first patient in its PATHFINDER clinical trial evaluating ibezapolstat in patients with multiply-recurrent Clostridioides difficile infection (rCDI), a condition affecting up to 40% of patients treated with vancomycin after multiple prior episodes.

Fully funded pilot trial targets approximately 20 patients with severe recurrence history

The Phase 2 PATHFINDER study is a multicenter, open-label, single-arm trial enrolling patients who have experienced at least three CDI episodes within the past 12 months. Participants receive ibezapolstat for 14 days, with assessments for Clinical Cure at Day 16, Sustained Clinical Cure at Day 42, and recurrence rates tracked through Week 24.

Lilly's Zepbound 15 mg Outpaces Wegovy HD by 4.5% in New Weight-Loss Analysis

Image
Lilly's Zepbound 15 mg Outpaces Wegovy HD by 4.5% in New Weight-Loss Analysis

Indianapolis – September 29, 2026 -- Eli Lilly and Company said a new indirect treatment comparison shows Zepbound (tirzepatide) 15 mg produced 4.5% greater body-weight loss than Novo Nordisk's Wegovy HD (semaglutide 7.2 mg) in adults with obesity, intensifying the competitive battle in the obesity-drug market. The 10 mg dose of Zepbound delivered 3.2% greater weight reduction than Wegovy HD, according to data presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan.

Providence Therapeutics Forms Oncology Advisory Board for mRNA Vaccines

Calgary – September 29, 2026 -- Providence Therapeutics Holdings, Inc. has formed its first Clinical Advisory Board to guide development of its therapeutic mRNA cancer vaccine programs, including a personalized vaccine for pediatric brain cancer and off-the-shelf precision therapies for solid tumors.

Chief Medical Officer Leon Rozen chairs new four-member advisory panel

Dr. Rozen leads the board, which brings in Ezra Cohen, MD; Melinda Merchant, MD, PhD; and John Powderly, MD, to steer clinical strategy for the company's cancer vaccine pipeline.

Tempus AI oncology chief joins board with immunotherapy track record

Ezra Cohen currently serves as Chief Medical Officer for Oncology at Tempus AI. He previously held roles as Professor of Medicine and Division Chief of Hematology/Oncology at the Moores Cancer Center, University of California, San Diego.

Ozempic Dose Escalation Cuts Cardiovascular Risk 6% Versus Mounjaro Switch

Image
Ozempic Dose Escalation Cuts Cardiovascular Risk 6% Versus Mounjaro Switch

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

Retrospective analysis covers 636,525 patients on semaglutide 1 mg

The COMPETE SWITCH Cardiovascular study used Komodo Health's Healthcare Map claims database, spanning January 2018 to September 2025, to compare outcomes for patients escalating from semaglutide 1 mg to 2 mg against those switching to tirzepatide at doses up to 15 mg. The cardiovascular cohort included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, tracked via an intention-to-treat approach for death, heart attack, and stroke.

Deloitte: Proactive Care Could Unlock $527B in U.S. Women's Health Spending

Image
Deloitte: Proactive Care Could Unlock $527B in U.S. Women's Health Spending

New York – – September 29, 2026 -- Deloitte analysis projects that shifting U.S. healthcare from reactive treatment to proactive, life-stage-aware care could generate $527 billion in additional potential spending on women's health by 2030 compared with a baseline trajectory.

Deloitte models a 20-year health span gain from earlier intervention

Under a prevention and improved disease-management scenario, Deloitte's actuarial Future of Health model — built on five years of medical and pharmacy claims data from nearly 60 million lives — estimates women's health span could increase by up to 20 years in the long run. The firm's report, "How a $527 billion growth opportunity in women's health can improve health outcomes," compares a baseline 2030 spending trajectory against a scenario emphasizing earlier detection and management across 22 disease states.

LUNGevity Commits $2M to Two AI-Driven Lung Nodule Diagnostic Trials

Image
LUNGevity Commits $2M to Two AI-Driven Lung Nodule Diagnostic Trials

Washington, D.C. – September 29, 2026 -- LUNGevity Foundation has committed $2 million to fund two three-year clinical research projects aimed at improving the diagnosis of indeterminate pulmonary nodules (IPNs), a condition affecting more than 1.5 million Americans annually after routine chest CT scans.

The funding, awarded through the 2026 RTFCCR/LUNGevity Early Detection Award in partnership with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), targets a diagnostic gap that currently forces many patients into unnecessary invasive procedures or prolonged uncertainty when non-invasive tools fail to determine whether a lung nodule is benign or malignant.

Innovent's IBI3003 Hits 84.6% Response Rate in Myeloma Trial

San Francisco – September 29, 2026 -- Innovent Biologics reported an 84.6% overall response rate for its trispecific antibody IBI3003 at the recommended Phase 2 dose in heavily pretreated multiple myeloma patients, data presented in an oral session at the 23rd International Myeloma Society Annual Meeting 2026.

Trial identifies 360 μg/kg as the optimal dose after testing three dose levels

Among 26 patients treated at 360 μg/kg with a median follow-up of 7.57 months, median progression-free survival has not yet been reached. The cohort produced 11 stringent complete responses, 4 very good partial responses, and 7 partial responses. Response rates climbed to 94.7% among 19 patients who had received only 2 to 4 prior lines of therapy, and 92.3% among 13 patients without extramedullary disease.

Implantica's RefluxStop Draws Overflow Crowd at U.S. Launch Event

Washington D.C. – September 29, 2026 -- Implantica AG launched its FDA-approved RefluxStop device in the U.S. market at the American Foregut Society (AFS) 2026 Annual Meeting, drawing an over-capacity crowd of more than 120 surgeons and gastroenterologists that forced organizers to turn away additional attendees.

FDA approval opens U.S. market for non-encircling GERD device

Following its recent Premarket Approval (PMA) from the U.S. Food and Drug Administration, RefluxStop entered a U.S. GERD treatment market estimated at 78 million patients. Unlike conventional anti-reflux surgeries that wrap around the esophagus, RefluxStop is designed to restore natural anatomy without encircling the food passageway, aiming to reduce side effects such as dysphagia and inability to belch or vomit.